Molecular Quality Control Market Size, Share & Trends Analysis Report By Product (Independent Controls, Instrument-specific Controls), By Analyte Type (Single-analyte Controls, Multi-analyte Controls), By Applications (Infectious Disease Diagnostics, Oncology Testing, Genetic Testing), By End User (Diagnostic Laboratories, Hospitals, IVD Manufacturers & Contract Research Organizations, Academic & Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Emerging Trends in the Market

Shift toward advanced molecular diagnostics

The increasing adoption of advanced molecular diagnostics such as PCR and next-generation sequencing drives a transition toward the development of more complex and assay-specific quality control materials to match evolving testing technologies. Manufacturers expand capabilities to produce multi-analyte and instrument-compatible controls to ensure accurate performance across platforms. Laboratories rely more on these controls to maintain consistency and meet stringent regulatory standards. As a result, the market shifts toward highly specialized and technology-aligned quality control solutions.

Transition toward standardized, traceable products

The growing emphasis on regulatory compliance and laboratory shifts focus to standardized, traceable, and third-party quality control products to support audit readiness and quality assurance. The regulatory compliance primarily refers to standards such as ISO 13485 for medical devices, CLIA for clinical laboratories, FDA 21 CFR Part 11 for electronic records, and GLP/GMP guidelines for laboratory quality and safety. Manufacturers focus on developing validated and independent control materials that meet global regulatory expectations. Laboratories increase adoption of external quality controls to ensure reliability and reduce the risk of diagnostic errors. Thus, the market evolves with stronger demand for compliant and standardized quality management solutions.

Market Drivers

Integration of multiplex testing panels and adoption of decentralized testing drives market

The rising integration of multiplex and syndromic testing panels increases demand for highly versatile molecular quality control materials. This demand impacts the market by requiring controls that can validate multiple targets and pathogens within a single assay run. Manufacturers respond by expanding supply of multi-analyte and panel-specific controls that align with complex testing workflows. CDC’s global TB proficiency testing now covers ~1,400 testing sites across 27 countries, and over 400 laboratories helped achieve international accreditation through quality management programs. These products help laboratories ensure accuracy across broader diagnostic panels without increasing operational burden. This drives market growth with stronger demand for advanced and comprehensive quality control solutions.

The increasing use of decentralized and near-patient molecular testing increases demand for stable and easy-to-use quality control materials, creating a need for controls that perform reliably outside traditional laboratory environments. Thus, the demand for room-temperature stable and user-friendly control formats to reduce handling complexity increases and support consistent testing performance across diverse and resource-limited settings. This drives market expansion with growing adoption of quality controls in decentralized diagnostic environments.

Market Restraints

Premium pricing and limited availability of standardized reference materials restrains molecular quality control market growth

The high cost of advanced molecular quality control materials acts as a key restraining factor in the market. Premium pricing of multi-analyte and third-party controls increases the operational burden for laboratories, especially in cost-sensitive settings. Budget constraints limit frequent usage and restrict adoption of comprehensive quality control protocols. This slows market growth as demand remains uneven across regions and laboratory tiers.

Limited availability of standardized reference materials for emerging and rare targets acts as another restraining factor in the market. Gaps in reference standards create difficulty in developing reliable and universally accepted quality control products. This leads to variability in test validation and reduces confidence in quality assurance processes. This limits adoption as laboratories face uncertainty in ensuring consistent performance across evolving molecular assays.

Market Opportunities

Expanding personalized medicine and growing adoption of digital laboratory systems offer growth opportunities for molecular quality control market players

The expansion of personalized medicine and companion diagnostics offers growth opportunities for players to cater to highly specific patient-matched molecular quality control demand from laboratories require controls that align with targeted therapies and biomarker-driven testing. Manufacturers develop customized and disease-specific control solutions to support precision diagnostics. These innovations enhance test accuracy and strengthen clinical decision-making. The market evolves with greater demand for tailored quality control products that support advanced therapeutic approaches.

The growing adoption of digital and cloud-connected laboratory systems enable integration of quality control data with real-time analytics platforms. Thus, laboratories seek more automated and data-driven quality management processes. Manufacturers invest in smart quality control solutions that connect with laboratory information systems and provide continuous performance monitoring. These capabilities improve efficiency and reduce manual intervention in quality assurance workflows. The market progresses toward integrated and intelligent quality control ecosystems with enhanced data utilization.

Regional Insights

North America: market dominance through high healthcare spending and extensive network of diagnostic laboratories and research institutes

North America dominated the market with the largest share of 38% in 2025. High healthcare spending in North America plays a critical role in driving the molecular quality control market. This enables widespread adoption of molecular testing methods such as PCR, real-time PCR, and next-generation sequencing (NGS), all of which require stringent and continuous quality control to ensure accuracy and reproducibility. High spending across the region also supports large-scale testing volumes for infectious diseases, oncology, and genetic conditions, while ensuring adherence to strict regulatory frameworks and accreditation standards. Consequently, healthcare providers and diagnostic laboratories regularly procure high-quality molecular control products, reinforcing North America’s dominance in the global market.

The US has an extensive network of diagnostic laboratories and research institutes, which significantly supports the molecular quality control market. The country hosts thousands of clinical and private diagnostic labs, academic research centers, and specialized molecular testing facilities that perform routine and high-volume testing for infectious diseases, oncology, and genetic conditions. These laboratories rely heavily on quality control solutions to maintain accuracy, ensure reproducibility, and comply with regulatory standards such as CAP, CLIA, and FDA requirements. In addition, leading research institutes and genomic centers continuously adopt advanced technologies like PCR, RT-PCR, and NGS for clinical and translational research, further driving the demand for robust molecular quality control products.

In Canada, the growing demand for molecular diagnostics and quality control solutions is driven by the country’s strong public healthcare system and increasing adoption of advanced testing technologies. Canadian hospitals, diagnostic laboratories, and research institutes are expanding their use of PCR, next-generation sequencing (NGS), and multiplex testing for infectious diseases, oncology, and genetic screening. Canada’s laboratories are increasingly seeking accreditation under international standards like ISO 15189 through bodies such as Accreditation Canada and the Canadian Society for Medical Laboratory Science (CSMLS). This pushes labs to adopt standardized quality control protocols in molecular testing to meet accreditation requirements.

Asia Pacific: fastest growth through increasing burden of diseases and strong regulatory compliance and quality standards in laboratories

The Asia Pacific region is expected to be the fastest-growing region in the market during the forecast period at a CAGR of 7%. The Asia-Pacific region is witnessing a rapidly increasing burden of diseases, which is driving the demand for molecular quality control solutions. High prevalence of infectious diseases requires frequent and large-scale molecular testing in hospitals and diagnostic laboratories. Simultaneously, rising cancer incidence, particularly breast, lung, and colorectal cancers in countries like China, Japan, and India, along with increasing screening for genetic and hereditary disorders, has expanded the need for precise and reliable diagnostics. This growing disease burden drives higher testing volumes, creating a strong requirement for both single-analyte and multi-analyte quality control solutions to ensure accuracy, reproducibility, and regulatory compliance across the region.

In China, government initiatives play a pivotal role in driving the molecular quality control market by strengthening precision medicine, genomics research, and infectious disease testing. Programs such as the China Precision Medicine Initiative and increased funding for genomics and molecular diagnostics research aim to advance personalized healthcare and early disease detection. Public health campaigns and regulatory support for infectious disease screening have expanded the adoption of advanced molecular diagnostics in hospitals and laboratories. The 2025 updates to the Infectious Disease Prevention and Control Law mandated enhanced laboratory testing standards and rapid reporting of notifiable diseases and encouraged hospitals and public health labs to implement advanced molecular diagnostic technologies such as PCR and next-generation sequencing to improve early detection and outbreak response.

In Japan, strong regulatory compliance and high-quality standards in laboratories significantly support the molecular quality control market. Laboratories in hospitals, diagnostic centers, and research institutes adhere to strict national and international guidelines, ensuring accuracy, reliability, and reproducibility in molecular testing. Regulatory frameworks mandate rigorous quality assurance protocols for PCR, NGS, and other advanced molecular diagnostics, particularly for oncology, infectious disease, and genetic testing. A future demographic forecast shows that Japan’s percentage of people aged 65 and older will rise to over 38.4 % by around 2065, leading to higher depend on health services and related testing, which increases routine use of molecular assays for early detection and monitoring and thereby drives demand for reliable QC products that validate test performance.

By Applications

The infectious disease diagnostics segment accounted for the largest share of 50% in 2025. This segment includes testing for diseases such as HIV, hepatitis, tuberculosis, influenza, and COVID-19. The growth in this segment is driven by high global testing volumes, the need for routine and rapid diagnostic accuracy, and widespread adoption of PCR and RT-PCR technologies.

The oncology testing segment is expected to grow at a CAGR of 8% during the forecast period. The growth is driven by the rising prevalence of cancers, increasing use of liquid biopsies and tumor profiling, and the adoption of next-generation sequencing (NGS) and multiplex diagnostic technologies. Molecular quality control solutions are critical in oncology testing to ensure accuracy, sensitivity, and reproducibility in detecting genetic mutations, tumor markers, and other critical biomarkers.

By Product

The instrument-specific controls segment is projected to grow at a CAGR of 5.5% over the forecast period. Their adoption is particularly strong among established laboratories and IVD manufacturers, where validated systems demand instrument-specific quality controls to meet strict CAP, CLIA, and FDA standards. Growth is driven by the need for high accuracy, sensitivity, and regulatory compliance in proprietary diagnostic systems.

The independent controls segment is projected to grow at a CAGR of 7% over the forecast period. Growth is driven by their compatibility across multiple instruments and platforms, providing laboratories with flexible and cost-effective quality assurance solutions. Independent controls are increasingly adopted by diagnostic laboratories, hospitals, and research institutes that operate diverse testing systems and require reliable quality control without being limited to a single manufacturer’s instrument.

By Analyte Type

The single-analyte controls segment is projected to grow at a CAGR of 6% during the forecast period. These controls are designed for target-specific testing, such as detecting a single pathogen or biomarker, and are widely used in routine diagnostic workflows across hospitals, diagnostic labs, and research institutes. Growth in this segment is driven by the need for high accuracy and reproducibility in specialized assays, particularly in infectious disease testing where precision is critical.

The multi-analyte controls segment is projected to grow at a CAGR of 8% during the forecast period. Multi-analyte controls are particularly favored in laboratories seeking to streamline workflows while maintaining accuracy and regulatory compliance. Growth is driven by the increasing adoption of multiplex PCR, next-generation sequencing (NGS), and high-throughput testing, which allow laboratories to test multiple targets simultaneously.

By End User

The diagnostic laboratories segment accounted for the largest share of 45% in 2025. Growth in this segment is driven by the high volume of routine molecular testing for infectious diseases, oncology, and genetic disorders. These laboratories rely heavily on quality control solutions to ensure accuracy, reproducibility, and compliance with regulatory standards such as CAP, CLIA, and ISO.

The hospitals segment is projected to grow at a CAGR of 7% over the forecast period. Growth is driven by the increasing adoption of in-house molecular diagnostic testing and the expansion of hospital-based laboratories. Hospitals are investing in advanced PCR, NGS, and multiplex testing platforms to meet rising demand for rapid infectious disease detection, oncology diagnostics, and genetic screening.